Onyx Biotec Services IPO Highlights
| Detail | Information |
|---|---|
| IPO Dates | November 13, 2024 to November 18, 2024 |
| Price Range | ₹58 to ₹61 per share |
| Face Value | ₹10 per share |
| Net Issue Size | 48,10,000 shares worth ₹29.34 Crores |
| Fresh Issue | 48,10,000 shares worth ₹29.34 Crores |
| Offer for Sale | Not Applicable |
| Listing | NSE SME |
| Issue Type | Book Built Issue IPO |
| IPO DRHP | Click Here |
| IPO RHP | Click Here |
What is GMP of Onyx Biotec Services IPO Today?
As of November 19, 2024, the Grey Market Premium (GMP) for the Onyx Biotec IPO is ₹15. This indicates that the shares are expected to list at approximately ₹76 per share, showing a potential listing gain of ₹15 or 24.59% over the issue price of ₹61.
Note: GMP is an unofficial indicator and is based on market speculation; it does not guarantee actual listing performance.
Important Dates to Remember
| Event | Date |
|---|---|
| IPO Opening Date | 13 November, 2024 (Wednesday) |
| IPO Closing Date | 18 November, 2024 (Monday) |
| Allotment Date | 19 November, 2024 (Tuesday) |
| Refund Initiation | 20 November, 2024 (Wednesday) |
| Credit of Shares in Demat Account | 20 November, 2024 (Wednesday) |
| Listing Date | 21 November, 2024 (Thursday) |
Company's Financial Metrics
| Period | Period Ended 31 May, 2024 (Amount in Lakhs) | Financial Year 2024 (Amount in Lakhs) | Financial Year 2023 (Amount in Lakhs) | Financial Year 2022 (Amount in Lakhs) |
|---|---|---|---|---|
| Total Assets | 7476.57 | 7413.58 | 5872.36 | 3683.84 |
| Total Revenue | 1054.11 | 5387.43 | 3961.65 | 4498.09 |
| Total Expense | 779.01 | 4546.66 | 3502.40 | 3922.30 |
| Profit After Tax | 130.77 | 303.16 | 184.46 | 335.29 |
| Company’s Net Worth | 2618.64 | 2487.87 | 1820.16 | 1637.59 |
| Total Reserves & Surplus | 1286.42 | 1155.65 | 1230.00 | 1047.43 |
Performance Metrics Overview
| Key Performance Indicator | Value (FY 2024) |
|---|---|
| ROCE | 3.71% |
| ROE | 4.99% |
| Price to Book Value | 3.1 |
| EBITDA Margin (%) | 15.41% |
| After Tax Profit Margin (%) | 12.42% |
| Debt to Equity Ratio | 1.21 |
| Return on Net Worth | 4.99% |
| Net Asset Value | 18.67 |
Investor Categories and Lot Sizes
| Application | Lot | Number of Shares | Amount (in ₹) |
|---|---|---|---|
| Retail Investor (Min. Lot) | 1 | 2000 | 122000 |
| Retail Investor (Max Lot) | 1 | 2000 | 122000 |
| HNI (Min. Lot) | 2 | 4000 | 244000 |
Investors Reserve Quota
| Category | Shares Reserved |
|---|---|
| QIB | 49.89% of the Total Issue |
| Retail Investors | 35.04% of the Total Issue |
| Non-Institutional Investors | 15.07% of the Total Issue |
Cash Flow Insights
| Net Cash Flow | For the Period Ended May 31, 2024 | March 31, 2024 | March 31, 2023 | March 31, 2022 |
|---|---|---|---|---|
| Net Cash Flow from Operating Activities | -119.41 | 151.62 | 623.60 | 48.55 |
| Net Cash Flow from Investing Activities | 3.89 | -314.79 | -2,267.19 | -577.59 |
| Net Cash Flow from Financing Activities | 29.02 | 309.11 | 1,642.97 | 519.78 |
| Net Increase/(Decrease) in Cash | -86.50 | 145.94 | -428.95 | -9.26 |
State Wise Revenue Generation
| State | May 31, 2024 (Amount in Lakhs) | March 31, 2024 (Amount in Lakhs) | March 31, 2023 (Amount in Lakhs) | March 31, 2022 (Amount in Lakhs) |
|---|---|---|---|---|
| Jammu & Kashmir | 84.28 | 281.14 | 166.93 | 105.51 |
| Himachal Pradesh | 470.68 | 1,600.54 | 1,381.05 | 1,739.78 |
| Chandigarh | 0.59 | 27.13 | 3.63 | 0.13 |
| Uttarakhand | 160.37 | 880.15 | 580.48 | 573.93 |
| Haryana | 59.28 | 654.90 | 19.74 | 1.89 |
| Bihar | – | 20.54 | 2.86 | – |
| Sikkim | 16.74 | 305.47 | 352.11 | 622.66 |
| Madhya Pradesh | 85.69 | 817.05 | 1,045.94 | 801.44 |
| Gujarat | 25.15 | 193.23 | 53.87 | 82.78 |
| Daman | 4.31 | 53.72 | 142.93 | 381.99 |
| Maharashtra | 16.07 | 238.07 | 191.50 | 171.31 |
| Tamil Nadu | 6.71 | 21.07 | 2.51 | 3.09 |
| Telangana | 1.22 | 79.05 | 1.13 | 1.07 |
| Delhi | 5.37 | 30.81 | – | – |
| Jharkhand | – | 5.29 | – | – |
| Karnataka | 17.77 | 31.00 | – | – |
| Punjab | – | 3.80 | – | – |
| Rajasthan | 2.28 | 36.27 | – | – |
| Uttar Pradesh | 87.96 | 69.91 | – | – |
| West Bengal | 8.33 | 24.61 | – | – |
| Total Revenue | 1,052.81 | 5,374.88 | 3,948.19 | 4,486.14 |
Revenue Generated from Exports
| Country | May 31, 2024 | March 31, 2024 | March 31, 2023 | March 31, 2022 |
|---|---|---|---|---|
| Nepal | – | 1.13 | 0.93 | – |
| Denmark | – | – | 3.58 | 0.55 |
| Total Export | – | 1.13 | 4.51 | 0.55 |
(Amount in Lakhs)
Product-Wise Income Generation
| Product | May 31, 2024 (Amount in Lakhs) | March 31, 2024 (Amount in Lakhs) | March 31, 2023 (Amount in Lakhs) | March 31, 2022 (Amount in Lakhs) |
|---|---|---|---|---|
| Sterile Water for Injections | 499.04 | 3,200.49 | 3,918.91 | 4,486.14 |
| Dry Powder Injections | 548.53 | 2,053.51 | 26.34 | – |
| Dry Powder Syrup | 5.24 | 120.88 | 2.94 | – |
| Total | 1,052.81 | 5,374.88 | 3,948.19 | 4,486.14 |
Comparison with Industry Peers
| Company | EPS (₹) | P/E Ratio | Face Value (₹) |
|---|---|---|---|
| Suven Pharma | 11.80 | 83.92 | 1 |
| JB Chemicals | 35.66 | 53.63 | 1 |
| Onyx Biotec Ltd | 2.28 | – | 10 |
Industry Average PE Ratio
| Metric | P/E Ratio |
|---|---|
| Highest | 94.90 |
| Lowest | 55.30 |
| Average | 75.10 |
Key Objectives of Onyx Biotec Services IPO
The fund raised through this IPO would be used in the following purposes.
- To pay down certain loans and improve financial stability.
- To enhance production capabilities at their existing manufacturing unit.
- To set up advanced packaging lines for efficient processing of products.
- General Corporate Purposes
Onyx Biotec IPO: Key Strengths and Challenges
Strengths:
- The company has a diverse product range.
- Experienced leadership with deep industry knowledge.
- The company has a solid production infrastructure to make quality products
- The IPO funds will be used for upgrading facilities, that will enhance operational efficiencies.
Challenges
- The company is producing a very limited number of products.
- There’s considerable debt on the company.
- High competition in the pharmaceutical industry could impact profit margins.
- A significant portion of revenue comes from some specific regions which may affect it adversely if demand decreases.
Management & Promoter Group
- Naresh Kumar
- Fateh Pal Singh
- Sanjay Jain
| Promoters Shareholding | Number of Shares |
|---|---|
| Pre-Issue | 13,322,200 |
| Post-Issue | 18,132,200 |
The company has not paid dividend to its shareholders in the last three financial years.
Company: Horizon Management Private Limited
Email: merchantbanking@horizon.net.co
Phone: 033 4067533 | +91 9007364081
Website: www.horizonmanagement.in
Company: Mas Services Limited
Address: T-34, 2nd Floor, Okhla Industrial Area, Phase II, New Delhi – 110020
Phone: +91 11 26387281/83
Email: ipo@masserv.com
Website: www.masserv.com
Address: SCO 70, 2nd Floor, Sector 30-C, Chandigarh – 160030, Punjab, India.
Phone: +91 172 265 6384
Email: generalinfo@onyxbiotec.com
Website: www.onyxbiotec.com
Our Perspective for this IPO
The company’s financial performance cannot be considered very good and is inconsistent, making this IPO not looking very attractive. Investors should thoroughly analyze the IPO before applying and also consider their risk tolerance. Additionally, comparing this IPO with other investment opportunities in the market may provide better insights. It is advisable to consult with a financial advisor to ensure an informed decision, minimizing potential risks and safeguarding their capital.
Commonly Asked Questions
What is the opening and closing date for the Onyx Biotec Services IPO?
The IPO opens on 13 November, 2024 (Wednesday) and closes on 18 November, 2024 (Monday).
2. What is the price band for the Onyx Biotec Services IPO?
The price band for the Onyx Biotec Services IPO is set between ₹58 and ₹61 per share
3. What is the minimum lot size for retail investors in the Onyx Biotec Services IPO?
Retail investors need to bid for a minimum of 2000 shares, which amounts to an investment of ₹122,000
4. Who are the lead managers for this IPO?
The lead manager for Onyx Biotec Limited’s Initial Public Offering (IPO) is Horizon Management Private Limited.
5. Who is the registrar for the Onyx Biotec Services IPO?
The registrar is Mas Services Limited.
6. What are the main objectives of the IPO?
The funds will primarily be used to pay certain loans, to enhance production capacities and for working capital requirements.
7. On which stock exchanges, the shares will be listed?
The shares will be listed on the NSE SME Exchange.
8. What is the total issue size for the Onyx Biotec Services IPO?
The total issue size is 4810000 equity shares worth 29.34 Cr.
9. When will the allotment and refund process begin?
The allotment is scheduled for 19 November, 2024, and refunds will begin on 20 November, 2024.
10. When will the shares be credited to the Demat account?
Shares will be credited to investors’ Demat accounts on 20 November, 2024.
11. What is the expected listing date for the IPO?
The shares are expected to list on the stock exchange on 21 November, 2024 (Thursday).
“Looking for more IPO reviews? Check out our recent posts on other Main-board IPO & SME IPOs for the latest market updates.”
Ready to apply? Start your IPO application here.
Note: This article is based on the information received from the company’s official documents, including the Draft Red Herring Prospectus (DRHP) and Red Herring Prospectus (RHP). For up-to-date information on the Grey Market Premium (GMP) for the Onyx Biotec Services IPO, you may please check our Current GMP, where we will post the latest figures as soon as they are available.
Disclaimer: This article is for educational purposes only. We do not offer any advice on buying or selling securities. Please consult your financial advisor before investing in an IPO or any other securities to make sure that it suits your financial plans and risk tolerance.
Don’t miss out on the latest IPOs – Click here to Find Upcoming IPOs.
“Invest Smarter, Faster – Click Here to Open Your Free Demat Account Today!”
“If this article was useful to you, feel free to share it with others who might find it helpful. Your feedback is important, so drop your questions or thoughts in the comments—we’d love to hear from you!”
Looking for the latest updates on upcoming IPOs? Explore detailed insights, expert reviews, and key information on these trending IPOs:
Leave a comment